These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 37090727)

  • 21. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer.
    Ge Y; Ye T; Fu S; Jiang X; Song H; Liu B; Wang G; Wang J
    Front Immunol; 2023; 14():1114041. PubMed ID: 37153619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
    Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
    Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
    Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
    BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive Analyses and Immunophenotyping of LIM Domain Family Genes in Patients with Non-Small-Cell Lung Cancer.
    Li S; Liu L; Qu Y; Yuan L; Zhang X; Ma Z; Bai H; Wang J
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
    Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
    Elife; 2021 Aug; 10():. PubMed ID: 34406120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
    Larroquette M; Guegan JP; Besse B; Cousin S; Brunet M; Le Moulec S; Le Loarer F; Rey C; Soria JC; Barlesi F; Bessede A; Scoazec JY; Soubeyran I; Italiano A
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Popat S; Grohé C; Corral J; Reck M; Novello S; Gottfried M; Radonjic D; Kaiser R
    Lung Cancer; 2020 Jun; 144():76-84. PubMed ID: 32387684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-Cell RNA Sequencing Reveals the Heterogeneity of Tumor-Associated Macrophage in Non-Small Cell Lung Cancer and Differences Between Sexes.
    Yang Q; Zhang H; Wei T; Lin A; Sun Y; Luo P; Zhang J
    Front Immunol; 2021; 12():756722. PubMed ID: 34804043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective.
    Kashefizadeh A; Kazemizadeh H
    Clin Transl Oncol; 2023 Feb; 25(2):316-322. PubMed ID: 36180811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
    Zhu J; Yuan Y; Wan X; Yin D; Li R; Chen W; Suo C; Song H
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD011300. PubMed ID: 34870327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer.
    Wang Y; Chen R; Wa Y; Ding S; Yang Y; Liao J; Tong L; Xiao G
    Front Immunol; 2022; 13():829451. PubMed ID: 35251014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transformation to small cell lung cancer as a mechanism of resistance to immunotherapy in non-small cell lung cancer.
    Bar J; Ofek E; Barshack I; Gottfried T; Zadok O; Kamer I; Urban D; Perelman M; Onn A
    Lung Cancer; 2019 Dec; 138():109-115. PubMed ID: 31683093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-associated macrophages in non-small-cell lung cancer: From treatment resistance mechanisms to therapeutic targets.
    Huang Z; Xiao Z; Yu L; Liu J; Yang Y; Ouyang W
    Crit Rev Oncol Hematol; 2024 Apr; 196():104284. PubMed ID: 38311012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Attili I; Tarantino P; Passaro A; Stati V; Curigliano G; de Marinis F
    Lung Cancer; 2021 Apr; 154():151-160. PubMed ID: 33684660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting Immunometabolism Mediated by CD73 Pathway in
    Passarelli A; Aieta M; Sgambato A; Gridelli C
    Front Immunol; 2020; 11():1479. PubMed ID: 32760402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.